A Phase 1/2 Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 11 Apr 2017
At a glance
- Drugs Brentuximab vedotin (Primary) ; Bendamustine
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Seattle Genetics
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 07 Dec 2015 Results published at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition, as per Seattle Genetics media release.
- 07 Dec 2015 Results published in Seattle Genetics media release.